Opus Genetics, Inc. (IRD)vsRevolution Medicines Inc (RVMD)
IRD
Opus Genetics, Inc.
$4.18
+5.26%
HEALTHCARE · Cap: $339.35M
RVMD
Revolution Medicines Inc
$187.51
+0.12%
HEALTHCARE · Cap: $36.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Opus Genetics, Inc. generates 1515% more annual revenue ($11.98M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
IRD
Avoid19
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.1%
Fair Value
$5.99
Current Price
$4.18
$1.81 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
IRD is growing revenue faster at -50.6% — sustainability is the question.
IRD generates stronger free cash flow (-13M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 19/100). IRD offers better value entry with a 45.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases impacting vision. By leveraging advanced gene-editing technologies and a robust research foundation, Opus aims to fulfill critical unmet medical needs in ocular health. With a promising pipeline supported by active clinical trials and strategic collaborations, the company is well-positioned to make significant contributions to patient care while presenting compelling growth opportunities for institutional investors in the dynamic healthcare landscape.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?